NKTR
Nektar TherapeuticsNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.78B
P/E Ratio
—
EPS
$-9.40
Beta
1.18
52W High
$109.00
52W Low
$7.99
50-Day MA
$76.15
200-Day MA
$52.86
Dividend Yield
—
Profit Margin
-297.10%
Forward P/E
34.01
PEG Ratio
0.31
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Fundamentals
| Revenue (TTM) | $55.23M |
| Gross Profit (TTM) | $55.23M |
| EBITDA | $-129.75M |
| Operating Margin | -87.50% |
| Return on Equity | -217.90% |
| Return on Assets | -28.00% |
| Revenue/Share (TTM) | $3.27 |
| Book Value | $4.41 |
| Price-to-Book | 32.07 |
| Price-to-Sales (TTM) | 50.40 |
| EV/Revenue | 49.26 |
| EV/EBITDA | -6.50 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -25.30% |
| Shares Outstanding | $33.21M |
| Float | $26.87M |
| % Insiders | 0.45% |
| % Institutions | 56.83% |
Analyst Ratings
Consensus ($144.25 target)
1
Strong Buy8
Buy1
HoldData last updated: 4/29/2026